Join Now

Want news that’s as fresh as your morning coffee? Join our community and stay in the know!

VA awards $1.5 million to study using psychedelics for PTSD treatment

Date:

Share:

Veterans Affairs officials on Tuesday announced a $1.5 million grant to study MDMA-assisted therapy for post-traumatic stress disorder and alcohol use disorder among veterans, the first department-funded research on psychedelic benefits in more than five decades.

VA officials had announced in January plans to begin new studies on the beneficial use of psychedelic compounds for ailing veterans, but had yet to commit any funding to such projects.

Advocates for years have touted the potential positive impact of compounds like methylenedioxymethamphetamine (MDMA) in helping with mental health issues.

The newly-funded study will take place at the Providence VA Medical Center in Rhode Island and West Haven VA Medical Center in Connecticut. Researchers affiliated with Brown University and Yale University will oversee the work, and begin enrolling participants early next year.

“VA is on the cutting edge of clinical research for Veteran health, including in the investigation of psychedelics for mental health,” Under Secretary for Health Dr. Shereef Elnahal said in a statement. “This study will give us better insight into the potential of MDMA-assisted therapy as a treatment for veterans.”

Officials said the move is part of a broader effort to “gather definitive scientific evidence on the potential efficacy and safety of psychedelic compounds,” suggesting the research will not be limited to only this single study.

Treatments will be conducted in a clinical setting with strict safety protocols and using pharmaceutical-grade MDMA. The study is expected to take five years to complete.

Department officials said that despite the upcoming interest in the potential benefits from psychedelics, veterans should not use them as part of a self-treatment program. All veterans are encouraged to consult with their health care providers before making any decisions on new medications or therapies.

Leo covers Congress, Veterans Affairs and the White House for Military Times. He has covered Washington, D.C. since 2004, focusing on military personnel and veterans policies. His work has earned numerous honors, including a 2009 Polk award, a 2010 National Headliner Award, the IAVA Leadership in Journalism award and the VFW News Media award.

Unmatched Baby Essentials

baby

━ more like this

Our favorite early childhood education stories this year

Happy holidays, and to those of you who are celebrating today, Merry Christmas! I am so grateful for your readership this year. Reporting on...

Why the 1914 Christmas Truce changed nothing on the Western Front

By late December 1914 World War I had been raging for nearly five months. Had anyone really believed it would be “all over by...

The PlayStation 5’s Quietest Year Was One Of Its Best Yet

The PlayStation 5 has entered the latter stage of its lifecycle, Sony announced back in February. The fourth anniversary of the console has been...

2024 in review: Business – Defense One

Are AI defense firms about to eat the Pentagon? Competitors are becoming collaborators in the industry’s hottest segment.Patrick Tucker, Science & Technology EditorEighteen ways...

States want adults to return to college, but face many roadblocks in trying to help them do so

By the summer of 2018, it had been more than 30 years since Maronda Mims had started her college journey. She’d earned credits from...

LEAVE A REPLY

Please enter your comment!
Please enter your name here